Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients (PIPER)

  • End date
    Jan 22, 2023
  • participants needed
  • sponsor
    Institut Bergonié
Updated on 22 March 2022
measurable disease
epithelioid sarcoma


This is a biology driven, monocentric study, designed to identify biomarkers of activity of trabectedin in patients with advanced non-L soft-tissue sarcoma. The aim of this study is to implement high-throughput profiling technologies to identify predictive biomarkers of trabectedin efficacy through sequential tumor biopsies and blood sample collection in sarcoma patients.


The identification of predictive biomarkers of the clinical benefit of trabectedin is a crucial issue to identify potential responders particularly for non-L sarcomas. Considering that the molecular profile of STS can change over time, an analysis of archival tumor material may not be a reliable method to identify predictive biomarkers of response, and thus high-throughput technologies may be promising to identify STS markers for prediction of response to trabectedin. For study purpose, blood and tumor samples will be obtained for genetic and immunological profiling at baseline, during treatment by trabectedin and at disease progression.

Condition Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Solitary Fibrous Tumors, Hemangioendothelioma, Desmoplastic Round Cell Tumor, Synovial Sarcoma
Treatment trabectedin
Clinical Study IdentifierNCT04008238
SponsorInstitut Bergonié
Last Modified on22 March 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 18 years
Histology: undifferentiated pleomorphic sarcomas, epithelioid sarcomas, solitary fibrous tumors, hemangioendothelioma, desmoplastic round cell tumors, synovial sarcomas or other non-leiomyosarcoma/non-liposarcoma softtissue sarcoma. As per the Frech NCI recommendation, diagnosis must be reviewed or confirmed by the RRePS Network (Réseau de Référence en Pathologie des Sarcomes des tissus mous et des Viscères)
Locally advanced/unresectable and/or metastatic disease
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Appendix 1)
Measurable disease according to RECIST v1.1
Indication of trabectedin according to market authorization
At least one target lesion that can be biopsied for research
Women of childbearing potential must have a negative serum pregnancy test before study entry
Patient with a social security in compliance with the French law
Voluntary signed and dated written informed consent prior to any study specific procedure
Women must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of trabectedin. Men must agree to use a medically acceptable method of contraception throughout the treatment period and for 5 months after discontinuation of trabectedin. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >=1 year

Exclusion Criteria

Previous treatment with trabectedin
Known hypersensitivity to any of its components
Patients with an active serious or uncontrolled infection upon investigator judgement
Radiological evidence of symptomatic or progressive brain metastases
Abnormal coagulation contraindicating biopsy
Any medical and/or biological contra-indication to treatment by trabectedin as per market authorization specification (as per investigator judgement)
Patients unable to receive corticotherapy
Previous or current malignancies of other histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer
Evidence of severe or uncontrolled systemic disease (uncontrolled hypertension, active bleeding diatheses, or active Hepatitis B, C and HIV)
Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
Individuals deprived of liberty or placed under guardianship
Pregnant or breast feeding women
Previous enrolment in the present study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note